Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Nanoscale|December 7, 2017
Design of a wearable and shape-memory fibriform sensor for the detection of multimodal deformationLi Li, Peipei Shi, Li Hua, et al.Lung Cancer (Amsterdam, Netherlands)|July 20, 2012
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.American Journal of Hematology|June 2, 2011
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myelomaIrene M Ghobrial, Nikhil C Munshi, Brianna N Harris, et al.Journal of Experimental & Clinical Cancer Research : CR|December 8, 2022
The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-κB1 p105 to p50Chengming Gao, Guangming Zhou, Jie Shi, et al.Gut|October 14, 2025
KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathwayChengming Gao, Yahui Wang, Guangming Zhou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.Pageof 6